Abstract
Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and emotional and psychiatric disturbances. The genetic mutation is characterized by a CAG expansion, resulting in the formation of a mutant huntingtin protein with an expanded polyglutamine repeat region. Mutated huntingtin has been shown to impair a number of physiological activities by interacting with several factors. In particular, cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) are severely affected by mutant huntingtin. In this view, drugs targeted at counteracting CREB loss of function and BDNF decrease have been considered as powerful tools to treat HD. Recently, cyclic nucleotide phosphodiesterase (PDE) inhibitors have been used successfully to increase levels of CREB and BDNF in HD models. Indeed, PDE4, 5 or 10 inhibitors have been shown to afford neuroprotection and modulation of CREB and BDNF.
In this review, we will summarize the data supporting the use of PDE inhibitors as the therapeutical approach to fight HD and we will discuss the possible mechanisms of action underlying these effects.
Keywords: Phosphodiesterase inhibitors, cAMP, cGMP, BDNF, CREB, Huntington's disease.
Current Pharmaceutical Design
Title:Phosphodiesterases as Therapeutic Targets for Huntington’s Disease
Volume: 21 Issue: 3
Author(s): Francesca R. Fusco and Carmela Giampa
Affiliation:
Keywords: Phosphodiesterase inhibitors, cAMP, cGMP, BDNF, CREB, Huntington's disease.
Abstract: Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and emotional and psychiatric disturbances. The genetic mutation is characterized by a CAG expansion, resulting in the formation of a mutant huntingtin protein with an expanded polyglutamine repeat region. Mutated huntingtin has been shown to impair a number of physiological activities by interacting with several factors. In particular, cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) are severely affected by mutant huntingtin. In this view, drugs targeted at counteracting CREB loss of function and BDNF decrease have been considered as powerful tools to treat HD. Recently, cyclic nucleotide phosphodiesterase (PDE) inhibitors have been used successfully to increase levels of CREB and BDNF in HD models. Indeed, PDE4, 5 or 10 inhibitors have been shown to afford neuroprotection and modulation of CREB and BDNF.
In this review, we will summarize the data supporting the use of PDE inhibitors as the therapeutical approach to fight HD and we will discuss the possible mechanisms of action underlying these effects.
Export Options
About this article
Cite this article as:
R. Fusco Francesca and Giampa Carmela, Phosphodiesterases as Therapeutic Targets for Huntington’s Disease, Current Pharmaceutical Design 2015; 21 (3) . https://dx.doi.org/10.2174/1381612820666140826113957
DOI https://dx.doi.org/10.2174/1381612820666140826113957 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Editorial [Pharmacology and Therapeutic Activity of Purinergic Drugs for Disorders of the Nervous System]
CNS & Neurological Disorders - Drug Targets Obstacles and Opportunities for Cholinergic Drug Development in the Treatment of Cognitive Disorders
Current Pharmaceutical Design Early Features in Frontotemporal Dementia
Current Alzheimer Research Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Tau as a Molecular Marker of Development, Aging and Neurodegenerative Disorders
Current Aging Science Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology Donepezil: An Important Prototype to the Design of New Drug Candidates for Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Neurological Substrate of Central Auditory Processing Deficits in Children
Current Pediatric Reviews The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology Memory-Enhancing Drugs: A Molecular Perspective
Mini-Reviews in Medicinal Chemistry The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
Current Pharmaceutical Design CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
Current Neuropharmacology Lifestyle Patterns as a Modifiable Risk Factor for Late-life Cognitive Decline: A Narrative Review Regarding Dementia Prevention
Current Aging Science One-Pot Multi-Component Route to Propargylamines Using Zinc Oxide Under Solvent-Free Conditions
Combinatorial Chemistry & High Throughput Screening Implications of Parkinson’s Disease Pathophysiology for the Development of Cell Replacement Strategies and Drug Discovery in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?
Current Pharmaceutical Design Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders
Current Protein & Peptide Science